All participants exited the analysis by May 31, 2010, except for individuals who had become contaminated with HIV, had been pregnant, or had a continuing severe adverse event at exit; we followed these individuals for to 1 1 additional year after discontinuation of the study medication up. The last participant go to occurred on March 11, 2011. Study Oversight The Botswana Health Study and Development Committee and the institutional review board at the U.S., a global biopharmaceutical company centered on oncology and endocrine therapy, announced the termination of its agreement with sanofi-aventis U today.S. dated March 5, 2009 for the advancement, commercialization and licensing of cetrorelix in benign prostatic hyperplasia for the U.S. Market, following a Company’s announcement last week of the results because of its European Phase 3 research for cetrorelix in BPH. Termination of the contract will succeed January 9, 2010.